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ABSTRACT
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder, compromising the 
motor neuron, characterized by progressive muscle weakness, with reserved prognosis. 
The diagnosis is based on inclusion and exclusion clinical criteria, since there is no specific 
confirmation test. The objective of this research is to critically examine the main diagnosis 
instrument - El Escorial revisited, from the World Federation of Neurology (1998). Of the 
540 patients with initial ALS diagnosis, either probable or definite, seen at UNIFESP-EPM, 
190 underwent thorough investigation, following regular clinical and therapeutic treatment 
for over two years. Thirty patients (15.78%) had their diagnosis completely changed. The 
false-positive diagnoses were related to: early age, clinical presentation of symmetry, 
weakness greater than atrophy, symptomatic exacerbation. In addition, three patients with 
myasthenia gravis developed framework for ALS, suggesting the post-synaptic disability 
as a sign of early disease. 
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Esclerose lateral amiotrófica: considerações sobre critérios diagnósticos
RESUMO
Esclerose lateral amiotrófica (ELA) é uma doença neurodegenerativa, que compromete 
o neurônio motor, caracterizada por fraqueza muscular progressiva, com prognóstico 
reservado. O diagnóstico é baseado na inclusão e exclusão de critérios clínicos, uma vez 
que não existe um teste de confirmação específica. O objetivo desta pesquisa é analisar 
criticamente o instrumento de diagnóstico principal - El Escorial revisited, da Federação 
Mundial de Neurologia (1998). Dos 540 pacientes com diagnóstico inicial de ELA, seja 
provável ou definitiva, vistos pela UNIFESP-EPM, 190 foram submetidos a investigação 
aprofundada, após tratamento clínico e terapêutico regular há mais de dois anos. Trinta 
pacientes (15,78%) tiveram seu diagnóstico mudado completamente. Os diagnósticos 
falso-positivos foram relacionados à idade precoce, a apresentação clínica da simetria, 
a fraqueza superior a atrofia, exacerbação sintomática. Além disso, três pacientes com 
miastenia gravis desenvolveram quadro de ELA, sugerindo a lesão pós-sináptica como 
um sinal precoce da doença.
Palavras-chave: esclerose lateral amiotrófica, diagnóstico correto, El Escorial revisited.
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Motor neuron diseases (MND) con-
stitute a group of neurodegenerative dis-
orders characterized by loss of neurons 
in the motor cortex, brainstem, and ven-
tral horn of the spinal cord. The clinical 
presentation depends on the involvement 
of upper motor neurons – UMN (weak-
ness, spasticity and hyperreflexia) or low-
er motor neurons – LMN (weakness, ab-
sent or diminished deep reflexes and fas-
ciculations). MND’s evolution can com-
promise both upper and lower limbs, as 
well as areas innervated by bulbar nerve 
fibers. MND patient survival is low, and 
is dependent on the initial involvement. 
Death usually occurs in 3 to 5 years after 
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The disorders include: progressive muscle atrophy 
(PMA), represented by a pure involvement of LMN; pri-
mary lateral sclerosis, characterized by progressive in-
volvement of pyramidal tract; progressive bulbar palsy 
(PBP), defined as the onset in the bulbar region; amyo-
trophic lateral sclerosis (ALS), as described by Charcot in 
1874, showing deterioration of UMN and LMN. 
The latter accounts for the most frequent clinical pre-
sentation (80% of total cases) and as a result many cen-
ters use the name ALS for the diseases with impairment 
of motor neuron2. 
The causes of motor neuron injury in MND/ALS re-
main incompletely understood. There are several mech-
anisms that may be involved in its development and a 
multifactorial disease is considered. The mechanisms re-
lated to ALS include the toxic effects caused by the mu-
tation of superoxide desmutase13, inclusion of abnormal 
protein aggregation, intermediary filaments disorganiza-
tion, anterograde and retrograde axonal transport change, 
microglial activation, excitotoxicity mediated by gluta-
mate, abnormalities in regulation of intracellular calci-
um and others. 
The diagnosis is based on clinical aspects. Therefore, 
we do not have a real biomarker for MND diagnosis.
Diagnosis
For many years, the only published criteria for the 
recognition of MND / ALS were done by Lambert, es-
tablished through electroneuromyography (ENMG)4. In 
1990, guidelines set by different researchers have been in-
corporated within the diagnostic criteria formulated by a 
Subcommittee on ALS of the World Federation of Neu-
rology (WFN), which culminated in the meeting and edit-
ing of the diagnostic criteria in El Escorial, Spain, in 19945.
ALS diagnosis is defined within the evidence of signs 
of impairment of lower motor neuron, by means of clin-
ical examination, electrophysiological or neuropatholo-
gycal changes, associated with clinically proven impair-
ment of upper motor neuron, with chronic and progres-
sive development. It is still necessary, for diagnosis, the 
absence of electrophysiological and pathological findings 
characteristic of other diseases that explain the degenera-
tion of motor neurons, as well as changes in neuroimag-
ing to justify the electrophysiological signals.
There has been, however, consensus among research-
ers, since certain clinical pictures and, above all, certain 
electrophysiological findings left doubt about the com-
pletion of diagnosis in some specific situations. Gener-
al neurologists and specialists in neuromuscular diseas-
es claimed additional difficulties for the necessary ALS 
early diagnosis.
The diagnostic criteria in El Escorial were reformu-
lated in 1998, at the World Federation of Neurology ALS 
meeting in Airlie House, Warrenton, Virginia, U.S. This 
revised document, known as El Escorial Revisited, was 
published by the WFN-ALS on the Web, with an aim at 
refining the diagnosis6.
New methods of electrophysiology, neuroimaging, 
immunohistochemistry and genome analysis were add-
ed for accuracy of diagnosis. The document El Escorial 
Revisited has been regarded as an important step to alle-
viate the difficulties in producing the diagnosis.
In a recent meeting, held in Japan, researchers im-
proved the diagnostic criteria and formulated “Awaji 
criteria”7. There was a reformulation of electromyogra-
phy, adding fasciculation with signal of neuronal damage, 
and inclusion new methods of diagnosis with transcrani-
al magnetic stimulation, voxel based morphometry and 
diffusium tensor imaging. 
Despite the diagnostic criteria established by the 
WFN, aided by more refined laboratory tests for diseas-
es that mimic ALS, accompanied by recent advances in 
imaging techniques, incorrect diagnosis is not infrequent. 
In previous studies, 45% of ALS patients presented ini-
tial wrong diagnosis and 25% of these were performed 
by neurologists. 
In addition, there is a long waiting period between the 
outset of symptoms and the diagnosis. In an internation-
al multicenter study named ISIS Survey, with 201 ELA-
diagnosed patients, median time required to confirm di-
agnosis was 14 months, with a 2-month waiting period 
for the first appointment. It took 8 months for the first 
appointment with the neurologist and it took another 4 
months for neurologist’s diagnosis observation and re-
evaluation8. 
Systematic reviews of ALS patients, in the last de-
cade, have shown 9 to 10% of false-positive ALS diag-
nosis. These, primarily included in the group of ALS at 
El Escorial Revisited, have unusual developments, with a 
break of the progression of chronic and progressive motor 
involvement and the appearance of signs and symptoms 
uncommon in clinical course, leading to a careful review 
diagnostic, pointing to other diseases such as multifocal 
motor neuropathy (MMN) and Kennedy disease9,10.
The objective of this study is a critical analysis of the 
ALS diagnostic criteria based on clinical presentations of 
patients with atypical presentation of motor neuron disease.
METHOD 
The Motor Neuron Disease Unit at the Neuromuscu-
lar Diseases Clinic in UNIFESP-EPM, running regularly 
since 1999, has sought to follow the development of di-
agnostic criteria for MND / ALS. The current diagnostic 
criteria are those defined by the El Escorial Revisited, in 
which patients are subjected to a memorandum of clini-
cal research in the WFN, previously cited. 
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The outpatient monitoring is carried out under reg-
ular (at least quarterly) periodic consultations encom-
passing multidisciplinary orientation therapy. To the best 
characterization of the goals, these patients’ medical re-
cords were analyzed in retrospect, with an aim at espe-
cially identifying the following medical conditions: pa-
tients with ALS initial clinical diagnosis, with an illness 
history longer than two years, classified as probable or de-
fined ALS, with different clinical course from the initial 
diagnosis, then ruling out MND / ALS diagnosis. Patients 
characterized, initially, with other neuromuscular diseas-
es, evolving, later on, to classic aspects of MND / ALS. 
RESULTS
Of the 540 patients registered in the Clinic, 190 pa-
tients met the MND / ALS diagnostic criteria, comple-
mented with laboratory research in compliance with 
both research protocols and regular monitoring. Thirty 
of these patients (15.78%) had their diagnosis complete-
ly changed, during the clinical observation development 
period (Table 1).
On the other hand, three patients with initial symp-
toms and diagnosis of other neuromuscular diseases de-
veloped features typical of MND / ALS during the clinical 
evolution. They are male, aged between 55 and 58 years 
old, whose characteristics are described in Table 2.
The Motor Neuron Disease Unit is a reference ser-
vice, and last months, has been receiving a great number 
of patients with defined ALS, which reduces the number 
of false negative diagnosis in this work. 
Table 1. False-positive diagnosis: diagnosis review in patients who have amyotrophic lateral sclerosis with first diagnosis in tandem with 
El Escorial revisited criteria.
Gender Starting age in years Ethnicity Disease evolution in years Diagnosis
Male 28 Caucasian 5 Limb gardle muscular distrophy
Male 70 Caucasian 7 Hereditary spastic paraparesis
Male 72 Caucasian 6 Shy-Dragger syndrome
Male 68 Caucasian 6 Spastic paraparesis with disartry
Male 39 Caucasian 5 Inflammatory braquial plexitis
Male 48 Caucasian 9 Chronic inflammatory polineuropathy
Female 74 Caucasian 4 Monoclonal gamopathy
Male 18 Afro-american 7 Spinal muscular atrophy type III
Female 33 Caucasian 3 Multifocal motor neuropathy
Female 75 Caucasian 9 Chronic inflammatory polineuropathy
Male 54 Afro-american 4 Multifocal motor neuropathy
Male 41 Caucasian 11 Chronic inflammatory polineuropathy
Male 18 Afro-american 13 cervical spinal cord neoplasm
Female 50 Caucasian 10 Multiplex neuropathy
Male 44 Caucasian 5 X linked bulbar spinal atrophy
Male 63 Asian 6 X linked bulbar spinal atrophy
Male 42 Caucasian 8 Spinal muscular atrophy type III
Female 55 Caucasian 10 Multifocal motor neuropathy
Female 41 Afro-american 11 Multifocal motor neuropathy
Male 54 Caucasian 2 Chronic inflammatory polineuropathy
Male 46 Caucasian 6 Chronic inflammatory polineuropathy
Male 48 Caucasian 3 Multifocal motor neuropathy
Female 52 Caucasian 3 Multiplex neuropathy
Female 40 Caucasian 2 Multiplex meuropathy
Male 61 Caucasian 4 Chronic inflammatory polineuropathy
Male 66 Caucasian 4 Multifocal motor neuropathy
Female 34 Caucasian 3 Multifocal motor neuropathy
Male 44 Caucasian 6 Quadríceps neurogenic amyotrophic 
Male 32 Afro-american 13 Neurofibromatosis type I
Male 18 Caucasian 25 Hexosaminidase A deficiency
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DISCUSSION 
Despite the recent refinement of the World Federa-
tion of Neurology Consensus for ALS diagnosis, errone-
ous diagnosis is not infrequent. 
Even in an experienced ALS diagnostic service at the 
MND / ALS Clinic at UNIFESP-EPM, thirty patients out 
of a group of 190 with regular monitoring and laborato-
ry research for complete characterization of ELA, have 
had their initial diagnosis changed over time. These pa-
tients’ clinical presentations display features that can help 
in ALS diagnosis, especially as to what regards a defini-
tive diagnosis of this disease11. 
Age
The age of onset of first symptoms, usually at less than 
30, increases the proportion of the differential MND / 
ALS diagnosis. The early onset, represented by 5 of the 
30 patients with false positive diagnosis, displayed genetic 
abnormalities, including deficiency of the enzyme hexo-
saminidase A and B12, lack of expression of proteins of the 
cytoskeleton of cortical spinal tract in hereditary spas-
tic paraplegia13, amendment of the suppressor gene ex-
pression in the formation of neurinomas in the peripher-
al nervous system in neurofibromatosis type I, or abnor-
malities of muscle protein constituents of the cytoskele-
ton such as disferlina. 
Clinical forms of presentation
Unilateral/Bilateral – MND/ALS has, characteristi-
cally, unilateral initial presentation, involving most of the 
time limb distal regions, where roots C8-T1 and L5-S1 
are the most commonly affected, with ipsilateral or con-
tralateral progression to the other roots, in a progressive 
and cumulative manner. 
Forms with peculiar clinical presentation as the 
monomelic atrophy of Hirayama14, attended with atrophy 
of a limb, predominantly in the upper limbs, in youths, 
with self-progression or, in some cases, slow progres-
sion15. In 12 (40%) of the 30 false-positive cases, we found 
unilateral atrophy, due to the specific motor involvement 
linked to immunoglobulins, in the associated cases of the 
multifocal motor neuropathy or monoclonal gammopa-
thies16 related to autoimmune dyscrasies. 
The involvement of bilateral and symmetrical limbs, 
at the beginning of the clinical picture, makes ALS diag-
nosis less likely, suggesting a multirradicular pattern more 
often found in polirradiculopathies17 with inflammatory 
motor predominance. 
Proximal/Distal – Predominance of involvement of 
MND / ALS is distal, then, beginning with proximal limb 
forms, leaves room for doubt in diagnosis, especially if 
there are no signs of pyramid release. The forms called “flail 
in arms” or brachial paraplegia and the legs paraplegia, as 
early symptoms, have predominance of proximal involve-
ment and presents blurry forms of spinal muscular atrophy 
of the adult form, which have variability progression and 
different prognosis19. Kennedy’s disease, also called spinal 
bulbar atrophy, linked to the X chromosome20,21, with typ-
ical symptoms of proximal atrophy associated with bulbar 
involvement, was found in two patients with false positive 
diagnosis in our study, and two other patients were diag-
nosed with an adult form of spinal muscular atrophy, type 
III, all of whom required more follow-up, since they have, 
until now, 6 years of tracking with localized forms of in-
volvement. One patient with chronic neurogenic quad-
riceps amyotrophy22 and another one with spastic para-
paresis with dysarthria13 may later develop MND / ALS. 
The motor and distal involvement presents other dif-
ferential diagnoses such as multifocal motor neuropathy, 
characterized by MMSS asymmetric distal involvement, 
distal myopathies, hereditary motor neuropathies, which 
can provide the clinical motor aspects in a given moment, 
similar to MND / ALS. 
Acute/Subacute/Chronic – The evolutionary pattern 
that characterizes the MND/ALS presents, in most of its 
forms, a chronic progressive decrease of motor function, 
bodily involvement with sum of the territories, ranging, 
on average, between three and five years. 
The changes to this pattern, with acute or subacute 
evolution of motor deficits and stabilization of the dis-
ease with acute relapses are characteristic of autoim-
mune-driven diseases. Moreover, part of the slower evo-
Table 2. False-negative diagnosis (three patients).
Diagnosis Initial ENMG First simptoms
Time to ALS 
diagnosis in years 
Myasthenia gravis Absent LMN lesion 
CMAP decrement >10%
Fadigue and proximal weakness 4
Myasthenia gravis Absent LMN lesion 
CMAP decrement >19%
Fatigue and fatigability in arms 7
Myasthenia gravis Absent LMN lesion 
CMAP decrement >10% 
Dysphagia, dysphonia, fatigue and weakness in arms 3
ENMG: electroneuromyography; ALS: amyotrophic lateral sclerosis; LMN: lower motor neuron; CMAP: compound muscle action potential.
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lution, with onset of signs and symptoms over years of 
evolution, attests to other forms involving the degenera-
tive motor neuron. 
The presentation of typical clinical aspects of spinal 
muscular atrophy can display a wide variability in its evo-
lution as well as in its clinical presentation and are ex-
cluded from their diagnosis, often for long periods with 
follow-up monitoring, and they may show signs of prog-
ress and bulbar involvement in 20 to 30 years of the on-
set of symptoms23. 
More accentuated weakness than atrophy – ALS di-
agnosis depends on clear evidence of both compromised 
lower motor neuron and upper motor neuron. The com-
mitment of the LMN is clinically more easily identifiable 
through the presence of atrophy and fasciculations as 
well as electromyography analysis. We have evidence that 
UMN commitment is more unusual. Signs of pyramid re-
lease are not always marked and, only recently, non-inva-
sive tests to reveal cortical spinal tract commitment have 
been incorporated into the medical practice. 
The MRI examination with sequences ST1 with MTC 
and transcranial magnetic stimulation (TMS) has iden-
tified abnormalities in the cortical spinal tract, thus be-
coming a useful tool in ALS diagnosis26. In patients where 
there is no clinically defined involvement of motor tract, 
image and TMS analysis must be requested. In the ab-
sence of abnormalities, ALS diagnosis should be placed 
in suspicion. Moreover, the atrophy of the motor cor-
tex, with severe loss of grey substance (cell body) and 
its brain connections are highlighted by recent advances 
in radiology and proton emission through tomography 
(PET), which quantifies the metabolism of regional areas 
of motor cortex, associated with quantifying the volume 
by voxel, making early diagnoses possible27. Transcrani-
al magnetic stimulation has become an auxiliary method 
for early diagnosis through the quantification of the de-
crease in speed within the motor central nervous system 
in patients with MND / ALS28.
Pyramidal signs and muscle atrophy – Character-
istically in ALS, the signals of pyramidal release must be 
present at sites above the sites where the muscular at-
rophy is evident. The presence of muscle atrophy and 
signs of pyramid release below the region of common 
cord nerve in the diagnosis, refer to a myelopathy, thus 
one should consider various causes, including spinal cord 
compression, tumor, syringomyelia, syringobulbia. 
Temporal development – The abnormal temporal 
evolution, with a challenge in the chronic and progres-
sive course of disease that involves the motor neuron can 
characterize changes in their etiology, and thus open ther-
apeutic possibilities. 
Time becomes a factor in the diagnosis in both false-
positive and false-negative cases and should be seen in 
serial appointments, as well as abrupt changes in clini-
cal signs, complaints of uncharacteristic symptoms typi-
cal of a motor neuron degenerative disease and the evo-
lutionary course of the disease. Thus, the erroneous ear-
ly diagnosis or lack of introduction of a feasible therapeu-
tic measure would be deployed17,25. 
Electroneuromyography and nerve 
conduction studies (ENMG) 
Due to the lack of a definitive marker for MND / ALS 
diagnosis, the ENMG study is a key element not only to 
detect abnormalities consistent with the disease diagno-
sis, showing activity of acute neuropathy damage and re-
innervation30, but also to rule out possible syndromes that 
mimic MND / ALS. 
The examination must encompass all the spinal terri-
tories, that is, the four limbs plus the tongue (hypoglossal 
nerve), including the paravertebral, abdominal and tho-
racic muscles. In addition, there is search for conduc-
tion motor blocking, both distal and proximal, in upper 
and lower limbs. In the light of new findings, such as the 
emergence of sensory changes or sudden changes in the 
course of evolution of the clinical situation, the need for 
the repetition of ENMG examinations is not infrequent. 
Considering clinical experience in outpatient clinic of 
motor neuron disease, attention must be drawn to these 
clinical features, which were identified and valued, with-
out which many of our patients would have been attrib-
uted erroneous ALS diagnosis. 
Differential diagnoses that mimic the MND/ALS pres-
ent, as predominant syndromes, lower motor neuron in-
volvement, in which the major diseases are multifocal 
motor neuropathy, spinal muscular atrophy, or diseas-
es that affect the cortical spinal cord tract in its portion, 
such as neurofibromatosis type I and neoplasms of cer-
vical spine, degenerative involvement associated with en-
zyme deficiencies, as hexosaminidase A and B and spastin 
(hereditary spastic paraparesis), among others. 
The onset of unusual signs and symptoms in the clini-
cal course, in the follow up also give way to other diagno-
ses, as well as long-time survival. Systemic involvement 
associated with endocrinal abnormalities, gynecomastia, 
insulin resistance and high levels of testosterone have led 
us to diagnose Kennedy disease. 
In conclusion, patients who have had false-positive 
diagnosis presented certain clinical characteristics that 
would put the diagnosis in doubt. They are: [1] Age below 
30 at the beginning of clinical manifestation; [2] Form of 
initial clinical presentation with: abrupt installation, bilat-
eral and symmetrical muscular weakness, proximal com-
promising; [3] Clinical presentation with: muscular weak-
ness without corresponding atrophy, absence of pyrami-
dal signs in medullar regions below the region of com-
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mon cord nerve, variation of symptoms, new worsening 
symptoms; [4] Longer clinical evolution; [5[ ENMG: done 
incompletely, lack of information on motor conduction 
block investigation.
Albeit not specific, fatigue and fatigability can be early 
symptoms of MND/ALS, as seen in three patients.
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